Peptide library / Immune & defense / Zilucoplan
Zilucoplan
A macrocyclic peptide that blocks complement C5, approved for generalized myasthenia gravis.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Generalized myasthenia gravis with anti-AChR antibodiesFDA approved
How it is thought to work
Zilucoplan binds C5 and stops it from being cleaved, which prevents attack on the nerve-muscle junction.
What the evidence shows
The RAISE trial showed improved daily activity scores compared with placebo.
Safety and unknowns
A boxed warning covers serious meningococcal infections, so vaccination is required.
Regulatory status
FDA-approved as Zilbrysq in 2023.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Immune & defense
Bacitracin
FDA-approvedA cyclic peptide antibiotic found in many over-the-counter wound ointments.
Brilacidin
In clinical trialsAn experimental antibiotic mimic of host defence peptides.
Voclosporin
FDA-approvedA modified cyclosporine for lupus nephritis.
General information, not medical advice. Do not buy or inject unregulated peptides.